Conditioning regimens
| Regimen . | No. of patients . |
|---|---|
| Fludarabine (90-150 mg/m2) + cyclophosphamide (20-120 mg/kg) | 41 |
| Fludarabine (150-300 mg/m2) + busulphan (4-10 mg/kg) | 31 |
| Fludarabine (90-150 mg/m2) + melphalan (140 mg/m2) +/− alemtuzumab (100 mg/m2) | 63 |
| Fludarabine (150 mg/m2) + thiotepa (300 mg/m2) | 1 |
| Fludarabine (100 mg/m2) + busulphan (8 mg/kg) + etoposide (30 mg/kg) | 3 |
| Fludarabine (100mg/m2) + cyclophosphamide (60 mg/kg) + thiotepa (300 mg/m2) | 1 |
| Fludarabine (150 mg/m2) + BCNU (300 mg/m2) + melphalan (140 mg/m2) | 8 |
| BCNU (300 mg/m2) + etoposide (800 mg/m2) + cytarabine (800 mg/m2) + melphalan (140 mg/m2) +/− Campath-IG antibody | 18 |
| BCNU (300 mg/m2) + etoposide (800 mg/m2) + cytarabine (800 mg/m2) + melphalan (140 mg/m2) + fludarabine (150 mg/m2) | 1 |
| Cyclophosphamide (60-120 mg/kg) +/− thiotepa (300-600 mg/m2) | 10 |
| Fludarabine (150 mg/m2) + cytarabine (800 mg/m2) +/− idarubicin (15 mg/m2) | 9 |
| Busulphan (4 mg/kg) | 1 |
| TBI (2 Gy) | 1 |
| Regimen . | No. of patients . |
|---|---|
| Fludarabine (90-150 mg/m2) + cyclophosphamide (20-120 mg/kg) | 41 |
| Fludarabine (150-300 mg/m2) + busulphan (4-10 mg/kg) | 31 |
| Fludarabine (90-150 mg/m2) + melphalan (140 mg/m2) +/− alemtuzumab (100 mg/m2) | 63 |
| Fludarabine (150 mg/m2) + thiotepa (300 mg/m2) | 1 |
| Fludarabine (100 mg/m2) + busulphan (8 mg/kg) + etoposide (30 mg/kg) | 3 |
| Fludarabine (100mg/m2) + cyclophosphamide (60 mg/kg) + thiotepa (300 mg/m2) | 1 |
| Fludarabine (150 mg/m2) + BCNU (300 mg/m2) + melphalan (140 mg/m2) | 8 |
| BCNU (300 mg/m2) + etoposide (800 mg/m2) + cytarabine (800 mg/m2) + melphalan (140 mg/m2) +/− Campath-IG antibody | 18 |
| BCNU (300 mg/m2) + etoposide (800 mg/m2) + cytarabine (800 mg/m2) + melphalan (140 mg/m2) + fludarabine (150 mg/m2) | 1 |
| Cyclophosphamide (60-120 mg/kg) +/− thiotepa (300-600 mg/m2) | 10 |
| Fludarabine (150 mg/m2) + cytarabine (800 mg/m2) +/− idarubicin (15 mg/m2) | 9 |
| Busulphan (4 mg/kg) | 1 |
| TBI (2 Gy) | 1 |